Prevalence and factors associated with pulmonary arterial hypertension on maintenance hemodialysis patients in Kinshasa, Democratic Republic of Congo: a cross-sectional study.
Cardiovascular disease
Hemodialysis
Pulmonary hypertension
Systolic pulmonary arterial pressure
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
04 11 2020
04 11 2020
Historique:
received:
07
01
2020
accepted:
27
10
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
3
11
2021
Statut:
epublish
Résumé
Although cardiovascular diseases in particular Pulmonary Arterial Hypertension (PAH) is associated with, high morbid-mortality in chronic hemodialysis, but its magnitude remains paradoxically unknown in sub-Saharan Africa. The aim of this study was to evaluate the prevalence of PAH and associated factors in chronic hemodialysis in Sub-Saharan African population. In a cross-sectional study, patients treated with HD for at least 6 months in 4 hemodialysis centers were examined. PAH was defined as estimated systolic pulmonary arterial pressure (sPAP) ≥ 35 mmHg using transthoracic Doppler echocardiography performed 24 h after the HD session. Eighty-five HD patients were included; their average age was 52.6 ± 15.9 years. Fifty-seven patients (67.1%) were male. Mean duration of HD was 13.3 ± 11 months. With reference to vascular access, 12 (14.1%), 29 (34.1%) and 44 (51.8%) patients had AVF, tunneled cuff and temporary catheter, respectively. The underlying cause of ESRD was diabetes in 30 patients (35.3%). The prevalence of PAH was 29.4%. Patients with PAH had more hyponatremia (11 (44%) vs 10 (16.7%), p = 0.010). In multivariate analysis, unsecured healthcare funding (aOR 4, 95% CI [1.18-6.018]), arrhythmia (aOR 3, 95% CI [1.29-7.34]), vascular access change (aOR 4, 95% CI [1.18-7.51]) and diastolic dysfunction (aOR 5, 95% CI [1.35-9.57] were independently associated with PAH. One third of hemodialysis patients exhibit PAH, which is independently associated with low socioeconomic status (unsecured funding, vascular access change) and cardiovascular complications (arrhythmia, diastolic dysfunction).
Sections du résumé
BACKGROUND
Although cardiovascular diseases in particular Pulmonary Arterial Hypertension (PAH) is associated with, high morbid-mortality in chronic hemodialysis, but its magnitude remains paradoxically unknown in sub-Saharan Africa. The aim of this study was to evaluate the prevalence of PAH and associated factors in chronic hemodialysis in Sub-Saharan African population.
METHOD
In a cross-sectional study, patients treated with HD for at least 6 months in 4 hemodialysis centers were examined. PAH was defined as estimated systolic pulmonary arterial pressure (sPAP) ≥ 35 mmHg using transthoracic Doppler echocardiography performed 24 h after the HD session.
RESULTS
Eighty-five HD patients were included; their average age was 52.6 ± 15.9 years. Fifty-seven patients (67.1%) were male. Mean duration of HD was 13.3 ± 11 months. With reference to vascular access, 12 (14.1%), 29 (34.1%) and 44 (51.8%) patients had AVF, tunneled cuff and temporary catheter, respectively. The underlying cause of ESRD was diabetes in 30 patients (35.3%). The prevalence of PAH was 29.4%. Patients with PAH had more hyponatremia (11 (44%) vs 10 (16.7%), p = 0.010). In multivariate analysis, unsecured healthcare funding (aOR 4, 95% CI [1.18-6.018]), arrhythmia (aOR 3, 95% CI [1.29-7.34]), vascular access change (aOR 4, 95% CI [1.18-7.51]) and diastolic dysfunction (aOR 5, 95% CI [1.35-9.57] were independently associated with PAH.
CONCLUSION
One third of hemodialysis patients exhibit PAH, which is independently associated with low socioeconomic status (unsecured funding, vascular access change) and cardiovascular complications (arrhythmia, diastolic dysfunction).
Identifiants
pubmed: 33148221
doi: 10.1186/s12882-020-02131-x
pii: 10.1186/s12882-020-02131-x
pmc: PMC7640388
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
460Références
Kidney Int. 2013 Oct;84(4):682-92
pubmed: 23739239
Int J Nephrol. 2010 Sep 30;2011:283475
pubmed: 21151534
Saudi J Kidney Dis Transpl. 2008 Mar;19(2):189-93
pubmed: 18310865
Echocardiography. 2008 Feb;25(2):162-8
pubmed: 18269561
Int Urol Nephrol. 2014 Jan;46(1):141-9
pubmed: 23793619
J Am Soc Echocardiogr. 1994 Jan-Feb;7(1):27-35
pubmed: 8155331
Nephrol Dial Transplant. 2012 Oct;27(10):3908-14
pubmed: 22290987
Kidney Int. 1995 Jan;47(1):158-63
pubmed: 7731141
Circulation. 2000 Nov 28;102(22):2781-91
pubmed: 11094047
Circ Heart Fail. 2017 Jun;10(6):
pubmed: 28611127
Hemodial Int. 2006 Oct;10(4):356-9
pubmed: 17014511
Transplantation. 2008 Nov 27;86(10):1384-8
pubmed: 19034007
J Renal Inj Prev. 2016 Dec 04;6(2):122-126
pubmed: 28497088
Ren Fail. 2013;35(4):560-5
pubmed: 23438072
Chest. 2005 Oct;128(4):2918-32
pubmed: 16236969
Am J Cardiol. 1987 Mar 1;59(6):662-8
pubmed: 3825910
Respiration. 2007;74(5):503-10
pubmed: 17505128
Am J Kidney Dis. 2018 Jul;72(1):75-83
pubmed: 29429751
Hemodial Int. 2010 Oct;14(4):398-402
pubmed: 20854331
Am J Nephrol. 2017;45(2):107-114
pubmed: 27941345
Chest. 2005 May;127(5):1836-43
pubmed: 15888866
Int J Gen Med. 2010 Oct 05;3:279-86
pubmed: 21042428
Am J Kidney Dis. 2004 May;43(5):923-6
pubmed: 15112184
Nephrol Dial Transplant. 2005 Aug;20(8):1686-92
pubmed: 15840664
Isr Med Assoc J. 2000 Sep;2(9):684-9
pubmed: 11062769
Chest. 2003 Dec;124(6):2093-7
pubmed: 14665485
Chest. 2003 May;123(5):1577-82
pubmed: 12740276
Am J Nephrol. 2008;28(6):990-7
pubmed: 18635926
J Am Soc Nephrol. 2017 May;28(5):1340-1349
pubmed: 28174217